Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860123 | 0.88 | KDM4E (0.43) | KDM4EALDH1A1GAAHPGDMAOA | |
| SCHEMBL3970688 | 0.81 | PDE10A (0.56) | KDM4EALDH1A1GAAHPGDGPR3 | |
| SCHEMBL27943843 | 0.79 | TDP1 (0.52) | KDM4EALDH1A1GAAHPGDMAOA | |
| SCHEMBL9611245 | 0.78 | KDM4E (0.57) | KDM4EALDH1A1GAAHPGDMAOA | |
| SCHEMBL30774177 | 0.77 | MAOA (0.61) | KDM4EALDH1A1HPGDMAOAMAOB | |
| SCHEMBL2712314 | 0.77 | MAOA (0.61) | KDM4EALDH1A1HPGDMAOAMAOB | |
| SCHEMBL15413759 | 0.76 | CYP1A2 (0.40) | KDM4EALDH1A1GAAHPGDMAOA | |
| SCHEMBL12767717 | 0.75 | ERN1 (0.54) | KDM4EALDH1A1GAAHPGDGPR3 | |
| SCHEMBL8545852 | 0.74 | PDE10A (0.70) | PDE10AKMT2ADHODHCYP2D6TSHR | |
| SCHEMBL5469806 | 0.73 | MAOA (0.56) | KDM4EALDH1A1HPGDMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872490-B1 | ANTIPROLIFERATIVE BENZO[B]AZEPIN-2-ONES | HOFFMANN LA ROCHE (CH) | 2018-02-07 | — | — | EP | disclosed |
| US-9611224-B2 | Antiproliferative benzo [B] azepin-2-ones | HOFFMANN-LA ROCHE INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2897972-B1 | 2-OXO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2016-11-30 | — | — | EP | disclosed |
| US-9422331-B2 | 2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150353499-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES | HOFFMAN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150225449-A1 | 2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2015-08-13 | — | — | US | disclosed |
| EP-2897972-A1 | 2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2872490-A1 | ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014044622-A1 | 2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014009495-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225449-A1 | 2-OXO-2,3,4,5-TETRAHYDRO-1 H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER | H1-5, HRH2, TOP2B | KDM4E 963/4885ALDH1A1 812/4885GAA 3493/4885 |
| US-20150353499-A1 | ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES | CCNY, RB1, TOP2B | KDM4E 860/4885ALDH1A1 2545/4885GAA 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.